(Q51021854)

27 March 2018

title

Induction-related cost of patients with acute myeloid leukaemia in France. (English)

1 reference

27 March 2018

1 reference

Virginie Nerich

1

1 reference

27 March 2018

Bruno Lioure

2

1 reference

27 March 2018

Maryline Rave

3

1 reference

27 March 2018

Christian Recher

4

1 reference

27 March 2018

Arnaud Pigneux

5

1 reference

27 March 2018

Brigitte Witz

6

1 reference

27 March 2018

Martine Escoffre-Barbe

7

1 reference

27 March 2018

Marie-Pierre Moles

8

1 reference

27 March 2018

Eric Jourdan

9

1 reference

27 March 2018

Jean Yves Cahn

10

1 reference

27 March 2018

Marie-Christine Woronoff-Lemsi

11

1 reference

27 March 2018

publication date

28 January 2011

1 reference

27 March 2018

International Journal of Clinical Pharmacy

published in

1 reference

27 March 2018

volume

33

1 reference

27 March 2018

issue

2

1 reference

27 March 2018

page(s)

191-199

1 reference

27 March 2018

https://scigraph.springernature.com/pub.10.1007/s11096-010-9462-1

exact match

0 references

cites work

Hospital costs of renal transplant management

1 reference

https://api.crossref.org/works/10.1007%2FS11096-010-9462-1

Economic evaluations of leukemia: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-010-9462-1

Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-010-9462-1

Estimating log models: to transform or not to transform?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-010-9462-1

Economic burden of acute myeloid leukemia: a literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-010-9462-1

The economic costs of acute myeloid leukemia in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-010-9462-1

Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11096-010-9462-1

A study based on national DRG data to evaluate work load and practice relating to cancer patients in not-for-profit hospitals

21 January 2018

1 reference

12 December 2020

The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia

1 reference

12 December 2020

A program for medical use of information systems. Validity of calculation of direct costs for the initial treatment of acute myeloblastic leukemia

1 reference

12 December 2020

Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.

1 reference

12 December 2020

Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug.

1 reference

12 December 2020

Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades.

1 reference

12 December 2020

Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands

1 reference

12 December 2020

[Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification]

1 reference

12 December 2020

Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia.

1 reference

12 December 2020

10.1007/S11096-010-9462-1

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018